A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Orally Administered TERN-501 as Monotherapy as Well as in Combination With TERN-101 in Noncirrhotic Adults With Presumed Non-Alcoholic Steatohepatitis (NASH)

This is a Phase 2a Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Orally Administered TERN-501 as Monotherapy as well as in Combination with TERN-101 in Noncirrhotic Adults with Presumed Non-Alcoholic Steatohepatitis (NASH)

开始日期2022-06-28

申办/合作机构

Terns, Inc.

NCT04328077

/ Completed临床2期

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2a Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Orally Administered TERN-101 Tablets in Adult Patients With Presumed Non-Cirrhotic Non-Alcoholic Steatohepatitis (NASH)

This is a Phase 2, randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, efficacy, and pharmacokinetics (PK) of TERN-101 in non-cirrhotic NASH patients.

开始日期2020-06-18

申办/合作机构

Terns, Inc.

NL-OMON32962

/ CompletedN/A

A MULTIPLE ASCENDING DOSE PHARMACOLOGY, FOOD EFFECT AND DRUG INTERACTION STUDY OF LY2562175 IN HEALTHY ADULT SUBJECTS - LY2562175 MAD/DDI/FE study

开始日期2009-08-06

申办/合作机构

Lilly Research Laboratories

100 项与 LY-2562175 相关的临床结果

登录后查看更多信息

100 项与 LY-2562175 相关的转化医学

登录后查看更多信息

100 项与 LY-2562175 相关的专利（医药）

登录后查看更多信息

430

项与 LY-2562175 相关的文献（医药）

2026-01-01·EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Discovery of novel potent indazole-based FXR agonists via scaffold hopping for MASH treatment

Article

作者: Shi, Hang ; Tian, Ping ; Shi, Xin-Wei ; Li, Qing-Hua ; Shi, Da-Yu ; Yu, Jing ; Gao, Dingding ; Huang, Cheng

The farnesoid X receptor (FXR) plays a crucial role in regulating bile acid homeostasis, inflammation, fibrosis, as well as glucose and lipid metabolism, positioning it as a promising target for the treatment of Metabolic Associated Steatohepatitis (MASH). LMB763 (Nidufexor), a clinical-stage FXR agonist developed by Novartis, has demonstrated efficacy in alleviating hepatic steatosis, inflammation, and fibrosis in preclinical MASH models. Using LMB763 as a lead compound, a series of novel compounds were designed and synthesized via a scaffold hopping strategy. The lead compound E2 exhibited potent FXR agonist activity with an EC₅₀ value of 0.097 ± 0.009 μM and favorable hepatic microsomal metabolic stability. Additionally, compound E2 displayed good selectivity against related nuclear receptors, including LXRα/β, PPARα/γ/δ, PXR, and TGR5. In vivo evaluation confirmed that compound E2 improved hepatic steatosis in high-fat diet (HFD)-induced MASH mouse model. These findings highlight E2 as a promising candidate for further development and provide valuable insights into the design of selective FXR agonists for MASH treatment.

2025-11-01·EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Rational design and synthesis of 6-(piperazin-1-yl)imidazo[1,2-b]pyridazine derivatives as dual FXR/PPARδ agonists for treatment of pulmonary fibrosis

Article

作者: Lei, Hongrui ; Zhai, Xin ; Fan, Xue ; Xu, Sha ; Ren, Yuhang ; Yue, Lingfeng ; Jiang, Nan

Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive multifactorial lung disorder characterized by excessive deposition of fibrotic connective tissue. The activation of farnesoid X receptor (FXR) and peroxisome proliferator-activated receptor δ (PPARδ) demonstrated therapeutic efficacy in reducing fibrotic pathology, respectively, suggesting that dual FXR/PPARδ up-regulators may provide a prospective approach to address the polypharmacy dilemma in fibrotic diseases. Herein, the identification campaign of 6-(piperazin-1-yl)imidazo[1,2-b]pyridazine derivatives as FXR/PPARδ dual agonists was described through hybridation of FXR agonist GW-4064 and PPARδ agonist GW-0742. The following exhaustive in vitro FXR and PPARδ activation studies culminated in the optimization of compound 10g, which displayed potent dual-target activities with an FXR agonistic EC₅₀ of 12.28 nM and 69 % PPARδ activation at 100 nM. In a Bleomycin-induced murine in vivo pulmonary fibrosis model, 10g (40 mg/kg, QD) significantly attenuated collagen deposition and reduced the expression of α-SMA in lung tissue. Taken together, these results shed new light on the discovery of novel FXR/PPARδ agonists for the treatment of IPF.

2025-11-01·TOXICOLOGY LETTERS

Geniposide induces hepatotoxicity via the bile acid-induced activation of NLRP3 inflammasome and regulation of the FXR/PERK/TXNIP pathway

Article

作者: Hao, Xuliang ; Liu, Yixuan ; Liu, Baoyue ; Li, Huifang ; Cheng, Shenghui ; Wei, Yanming ; Jin, Zhinan

Gardenia jasminoides, as a widely used traditional Chinese medicine, excessive consumption of it may lead to severe liver injury. As the main hepatotoxic component in Gardenia jasminoides, the specific mechanism by which geniposide (GE) causes liver injury remains elusive. In this study, we conducted a systematic investigation of the effects of GE on bile acid (BA) metabolism and related signal transduction and inflammatory pathways in healthy Sprague-Dawley (SD) rats after oral administration of a 13-fold clinical equivalent dose (450 mg/kg) for 5 days. It is noteworthy that GE administration altered the content and composition of BAs and disrupted BA metabolism. At the same time, the expressions of farnesoid X receptor (FXR) and its downstream proteins bile salt export pump (BSEP) and sodium taurocholate cotransporting polypeptide (NTCP) are significantly inhibited. In addition, the inhibition of FXR will increase the signal transduction of the protein kinase R-like endoplasmic reticulum kinase (PERK)-thioredoxin-interacting protein (TXNIP)-nod-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome axis, thereby triggering cysteine protease-1 (caspase-1), leading to the release of inflammatory factors and worsening liver injury. The addition of the FXR agonist obeticholic acid (OCA) effectively reversed the expressions of the above proteins and mRNA, and alleviated the liver injury caused by GE by restoring BAs homeostasis and regulating the inflammatory pathway. Conclusion: GE causes severe liver injury by affecting bile acid metabolism and inflammatory pathways, and the inhibition of FXR is a crucial factor.

168

项与 LY-2562175 相关的新闻（医药）

2025-11-28

·博药

十年三转！Terns从MASH到“抗肿瘤”的绝境破局

2025年11月以来，有一家海外Biotech企业，短短一个月内（10月31日—11月26日），股价暴涨257.86%，登顶区间涨幅榜首，其名字为Terns Pharmaceuticals。而在其光辉的背后，从2016年创立至今的近10年里，“转型”是其主要代名词：核心管线与赛道调整围绕在侧。而正是这样的Terns Pharmaceuticals（拓臻生物，下称Terns），为何本月却能成为资本市场最大的香饽饽，其背后究竟隐藏着怎样“逆风翻盘”的逻辑？创立：专注MASH的最初梦想 2016年，钟伟东博士、Randy Halcomb博士与Martijn Fenaux博士因抗病毒药物研发关联而共同创立了Terns Pharmaceuticals，并由钟伟东博士担任创始人、CEO兼首席科学家。图片来源：医药魔方（Terns前官网）并且，作为创始人的三人均有不同程度的吉利德与诺华抗病毒药物研发背景：钟伟东博士：创立Terns前，曾任诺华抗病毒药物研发的全球负责人、吉利德科学生物部门高级总监，负责HCV、HBV及肝纤维化药物的研究，在开发新型抗丙肝病毒药物方面起到了关键作用。 Randy Halcomb博士：曾在吉利德科学担任药物化学主管，主导的研究项目涉及早期开发、高效筛选、化合物优化等多个阶段，研发的多种候选药物进入临床阶段。 Martijn Fenaux博士：曾在吉利德科学与诺华公司任职，领导了多种抗病毒药物的发现与开发，参与了研发已获准上市的家畜疫苗Fostera®PCV MH。而管线方面，Terns成立早期，业务专注于非酒精性脂肪性肝炎、肝纤维化与减重等代谢疾病领域，并在美国加州和中国上海张江设立了总部，是典型的“中美双基因”药企，核心管线部分则主要由外部引进获得： 2018年，从礼来引进3款MASH小分子药物的全球独家开发授权：法尼醇X核内受体（FXR）激动剂TERN-101、VAP-1抑制剂TERN-201以及一款NASH已知靶点的小分子药物。 2019年，从GENFIT公司引进PPARα/PPARδ双重激动剂Elafibranor在大中华区的独家开发和推广权益，用于治疗非酒精性脂肪性肝炎（MASH）和原发性胆汁性胆管炎（PBC）。数据来源：药智数据（点击查看大图，如有错误请指正）有意思的是，从以上信息和创始人背景来看，其专注领域明显更集中于抗病毒领域，但前期管线上，其领域却实际聚焦于代谢层面。但众所周知，即使放在整个代谢领域中，MASH新药研发也是难度最高的存在，彼时全球更无任何一款MASH新药获批，以至于后续GENFIT宣布Elafibranor治疗MASH的关键3期研究失败（现获批适应症为原发性胆汁性胆管炎）；TERN-201与TERN-202的临床研发状态也不再活跃（进度停留在2021/2022年），目前已从Terns官网被剔除；口服甲状腺激素受体-β（THR-β）激动剂TERN-501也被内部限制了研发支出（来源：摩根大通医疗健康年会）。很明显，Terns创立之初的这几年，MASH管线推进并不顺畅，这一点也为后续Terns重新调整赛道做好了铺垫。蜕变：“减肥”成为新希望如上述所言，自2021年Terns在纳斯达克上市以来，Senthil曾寄予厚望的TERN-101、TERN-201以及Elafibranor（MASH适应症）先后折戟，这使得彼时的Terns管线骤然“精简”（如下图）。图片来源：Terns招股书因此，Terns只能将研发精力集中于剩下两款新药，即TERN-501（MASH）与TERN-601（肥胖），严格意义上来说应该是TERN-601这一款。而事实上，TERN-601在其早期研发阶段也确实没让Terns失望，2023年6月首次在ADA 2023大会上公布临床前数据，引动全球资本市场关注；2024年9月，公布Ⅰ期试验结果，最高剂量组达到了4.9%的安慰剂调整平均体重减轻，震惊四座。图片来源：拓臻生物官网 BMO Capital Markets的分析师更是直接将TERN-601的I期研究结果与礼来的Orforglipron和辉瑞的Danuglipron等口服减重药进行了比较，主要结局读数上，TERN-601在减重数据上力压礼来的Orforglipron以及辉瑞的Danuglipron。而由于本质上TERN-601的结构与Danuglipron极其相似，或许也为其后续管线终止做出了预示（早前，辉瑞的Danuglipron已因肝脏安全性问题而停止开发）。图：TERN-601（左）与Danuglipron（右）的结构式对比图片来源：药化杂谈、Piney Banter 受此消息的影响，Terns当日的股价上涨16.77%。市值增至6.42亿美元，达上市以来最高峰。而之后Terns更是趁此机会宣布公开募股1.25亿美元，所得款项也将用于口服GLP-1激动剂的后续临床试验。很明显，此时的Terns首次感受到站上风口的感觉，其对TERN-601的未来也更加期待，对向GLP-1转型的决心也更加坚定。转折：放弃减肥，转战肿瘤新药研发 2023年底，随着礼来的替尔泊肽获FDA批准用于减重，临床数据显示72周平均减重20.2%（司美格鲁肽为13.7%），疗效优势显著。在此行情之下，市场开始重新审视这一红海内不同药品的价值，一些临床进展速度和疗效不佳的药物，率先成为资本去风险化的目标，GLP-1赛道逐渐由最初的大蓝海演变为竞争激烈的红海市场。而TERN-601正是其中之一。 2025年10月21日，Terns公布了小分子GLP-1受体激动剂TERN-601减重二期临床12周顶线数据。结果显示，12周最高安慰剂调整体重减轻率为4.6%，低于I期研究中报告的28天体重减轻率4.9%。此外，更关键的是研究过程中还有11.9%的TERN-601治疗患者因不良事件（AE）而停止治疗，其中包含3例3级肝功能检测（LFT）升高。图：Terns现有在研管线（TERN-601已被剔除）图片来源：Terns官网显然，以目前该药的有效性与安全性数据来看，其已无法与现有GLP-1形成有效竞争，因此Terns现任CEO Amy Burroughs在25年第二季度电话会议上表示，公司不再对代谢疾病领域的任何资产进行投资，转而全心投入肿瘤新药的研发。创立近10年，被寄予厚望的减肥资产也未能带领Terns走向辉煌，而回首望去，Terns手中似乎已只剩下TERN-701这唯一的翻身筹码。未来：聚焦白血病 2025年11月3日，Terns迎来历史性时刻，其股价在盘前交易中飙升超过65%，开盘后涨幅更是一度突破+80%。而这一戏剧性市场反应的背后，则是Terns抛弃减重资产后，专注肿瘤新药研发的最好回应。这一日，Terns Pharmaceuticals公布新一代BCR-ABL变构抑制剂TERN-701治疗CML一期临床数据，并将在ASH会议上做口头报告。 ASH会议作为全球血液学领域最高级别学术会议，每年要接收约15,000篇摘要，却仅有10%—15%的突破性报告将获口头报告资格，竞争极为激烈。并且ASH报告本身入选标准严苛，更是历年临床医生决策的关键影响因子。而另一方面，虽然目前CML治疗市场的主要份额主要属于变构TKI（如Asciminib），预计销售峰值超过30亿美元。但其他领域内仍存在严重未被满足的临床需求，比如Asciminib治疗过程中，仍有部分患者无法达到MMR（主要分子学反应）。图片来源：医药笔记而TERN-701的I期数据中，24周治疗周期后，不仅取得历史最佳MMR数据，更对Asciminib及其他TKI治疗失败的患者展现出60%—70%的MMR率，较现有产品历史数据提升至少2倍；同时安全性优异，3级及以上副作用发生率不足10%，治疗窗更宽。图片来源：拓臻生物总而言之，以目前TERN-701在CML治疗表现来看，其定位清晰，突破性集中在“难治型患者”与“持久选择性”两方面。更高选择性、更好的体内靶点覆盖和更宽的治疗窗口的TERN-701也充分验证了公司聚焦肿瘤研发的战略正确性，更推动该药有望快速推进至Ⅲ期临床，有望重塑CML治疗格局。小结十年沉浮，三次关键转型，Terns的每一步都踩在行业浪潮的节点上，也历经了创新药研发的残酷与无常。从MASH赛道的折戟沉沙，到减重领域的昙花一现，再到肿瘤赛道的柳暗花明，这家企业没有因屡次受挫而沉沦，反而以“壮士断腕”的勇气不断调整航向。最终以TERN-701在CML治疗中展现的突破性数据，不仅验证了其聚焦肿瘤研发的战略正确性，更让市场看到了这家老牌Biotech的创新韧性。而对于创新药行业而言，Terns的故事并非个例，道路之上如BioNTech、Metsera那样顺遂的发展之路终究只是少数，如Terns一般的创新者才是主体。同时，世界上也没有永远的蓝海赛道，更没有绝对的失败尝试，每一次管线调整都只是对临床需求的重新审视，每一次战略转型都是对生存机遇的奋力抓取。未来，随着 TERN-701进入后续临床阶段，Terns能否真正改写CML治疗格局，实现从“绝境求生”到“行业领跑”的跨越，仍需时间检验。但可以肯定的是，在创新药的漫漫长夜里，那些敢于试错、勇于转身的企业，终将在坚持中等到属于自己的曙光。而Terns的十年征程，也为无数挣扎中的Biotech写下了注脚：真正的创新，从来不是一条道走到黑，而是在黑暗中找准方向，逆光而行。博腾股份成立于2005年，主要为全球药企、生物科技公司、科研机构等提供从临床前研究到药品上市全生命周期所需的小分子药物、多肽与寡核苷酸药物、蛋白与偶联药物以及细胞与基因治疗药物等一站式服务解决方案，研发、生产、运营场地覆盖中国（重庆、上海、四川、江苏、江西、湖北）、美国、斯洛文尼亚、比利时、瑞士和丹麦等地。我们始终坚持以客户为中心，致力于为客户提供创新、可靠的全球化、端到端CDMO服务，让好药更早惠及大众。免责声明：本文仅作者个人观点的表达，文中观点不代表博腾及其所属子公司立场，亦不对本文所提供信息做任何形式的保证。同时，本文不做治疗方案推荐，也不承担因使用或依赖本文信息所产生的任何直接或间接的后果。如需获得治疗方案指导，请前往正规医院就诊。

2025-09-11

·FiercePharma

Intercept, after many setbacks, pulls liver disease drug Ocaliva in US

After attempts to earn a full approval for Ocaliva in primary biliary cholangitis, Intercept Pharmaceuticals is pulling the plug on the drug in the U.S. based on the request of the FDA. After years of regulatory struggles for Intercept Pharmaceuticals and its liver disease drug Ocaliva (obeticholic acid), the FDA has called time on the drug's run in the U.S. market. The agency placed Intercept's trials of obeticholic acid on a clinical hold and requested that the company voluntarily withdraw the drug from the market, where it has been cleared to treat certain patients with primary biliary cholangitis (PBC) since winning an accelerated approval in 2016. Despite Intercept's arduous efforts to obtain full approval for the drug, the company has obliged and will pull the med, it announced in a Sept. 11 press release. “While our view of Ocaliva’s benefit-risk profile differs from FDA’s, we respect its request and have made this difficult decision to provide clear guidance for patients and prescribers,” Intercept’s U.S. president Vivek Devaraj said in a statement. “We remain committed to innovation in hepatology and to serving the needs of patients and physicians.”The development marks the latest setback for Intercept's U.S. market prospects and comes after the FDA’s Gastrointestinal Drug Advisory Committee overwhelmingly voted against Intercept's data package at a meeting last year.Committee members weren’t swayed by Intercept’s clinical trials, nor was the FDA in its pre-meeting briefing documents. In its assessment, the FDA flagged the potential for the drug to put patients at greater risk of needing a liver transplant or death.Soon after the meeting, the FDA rejected Intercept’s bid for a traditional approval. But the agency did allow the drug to remain available for certain patients under its initial accelerated nod while it weighed safety data from a post-marketing study. Still, the company didn’t give up and pledged to generate additional data in support of its drug.But the hits kept on coming. Over in Europe, regulators ultimately snatched back Ocaliva’s marketing nod late last year after a holding period. The repeated setbacks in PBC weren't exactly unfamiliar territory for Intercept. The company had at one point hoped to market the drug as the first treatment for nonalcoholic steatohepatitis, which is now known as metabolic dysfunction-associated steatohepatitis (MASH).That situation saw a similar storyline play out, with two of the company's attempts to win the FDA’s favor falling short. Afterward, Intercept was forced to pivot from its MASH efforts to PBC, trimming a third of its workforce and winding down all MASH-related investments. It was after the MASH rejection that Intercept sold itself to Italian drugmaker Alfasigma in a deal worth about $800 million. At the time in 2023, the company was boasting $285.7 million in full-year 2022 sales for Ocaliva, its lone product.Intercept’s pipeline is made up largely of obeticholic acid, but it lists one other next-generation FXR agonist being tested in a phase 2a study for severe alcohol-associated hepatitis.

临床2期加速审批上市批准

2025-09-11

·Firstwordpharma

Intercept pulls Ocaliva from US market after FDA request

Intercept Pharmaceuticals is withdrawing its liver drug Ocaliva (obeticholic acid) from US shelves at the FDA's request, capping years of safety concerns and regulatory scrutiny. The move follows reports of liver failure in patients with primary biliary cholangitis (PBC), including deaths and transplants, even among those without advanced cirrhosis."We continue to believe the totality of clinical and real-world evidence supports Ocaliva's use for appropriate patients," said Vivek Devaraj, Intercept's US president. "While our view of Ocaliva's benefit-risk profile differs from FDA's, we respect its request and have made this difficult decision to provide clear guidance for patients and prescribers."The FDA has also ordered a halt to every Intercept trial of Ocaliva in the US.Cleared in 2016 under the FDA's accelerated pathway, the FXR agonist became entrenched as a second-line treatment option for PBC patients in combination with ursodeoxycholic acid in patients with an inadequate response to ursodeoxycholic acid (UDCA) or as monotherapy those who could not tolerate UDCA.However, its nine-year run on the market has been marred by the inclusion of boxed warnings – including one tied to dosing restrictions in patients with more advanced disease, and then another further restricting its use due to post-marketing reports of serious liver injury and liver failure in PBC patients with advanced cirrhosis – as well as a failed expansion into metabolic dysfunction-associated steatohepatitis. Regulators in Europe have already ordered the drug's withdrawal.Intercept, which was acquired by Italy's Alfasigma in 2023, said it will work with the FDA on the transition process.The US retreat comes amid a reshaping of the PBC market following the back-to-back approvals last year Gilead Sciences' Livdelzi (seladelpar) and Ipsen's Iqirvo (elafibranor), both PPAR agonists. Livdelzi so far appears to have the upper hand, according to a recent FirstWord survey of US specialists, with nearly two-thirds of respondents saying they prefer the drug over other second-line rivals, though pricing and coverage could hinder uptake (see – Physician Views Results: Livdelzi emerges as favourite among rivals, but headwinds haunt its path).Meanwhile, Zydus is preparing a US filing for saroglitazar, a dual PPAR alpha/gamma agonist that recently met its primary endpoint in a late-stage trial.

加速审批

100 项与 LY-2562175 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB16045

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
代谢功能障碍相关脂肪性肝炎	临床2期	美国	Terns, Inc.	2020-06-18
胆管炎	临床1期	美国	Terns Pharmaceuticals, Inc.	2019-07-17
血脂障碍	临床前	美国	Eli Lilly & Co.	2015-12-24

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05415722 (DUET, CTgov)	临床2期	代谢功能障碍相关脂肪性肝炎	162	TERN-501 (Arm 1: TERN-501 1 mg)	糧廠鏇膚構鬱遞窪觸顧(鹽糧夢醖齋膚鹽鏇襯壓) = 醖範獵鹹壓衊淵醖膚蓋齋築構範淵繭鏇鹽壓齋 (艱鑰遞艱繭齋窪構憲窪, 5.186) 更多	-	2025-03-12
NCT05415722 (DUET, CTgov)	临床2期	代谢功能障碍相关脂肪性肝炎	162	TERN-501 (Arm 2: TERN-501 3 mg)	糧廠鏇膚構鬱遞窪觸顧(鹽糧夢醖齋膚鹽鏇襯壓) = 顧獵簾獵顧醖淵繭製窪齋築構範淵繭鏇鹽壓齋 (艱鑰遞艱繭齋窪構憲窪, 5.740) 更多	-	2025-03-12
NCT04328077 (LIFT, EASL2022)	临床2期	代谢功能障碍相关脂肪性肝炎	100	TERN-101 15 mg	鹹廠選淵襯觸觸遞膚鬱(艱蓋鹽選膚膚膚製願鹹) = Pruritus AEs (including pruritic rash) were reported in 11 of 74 (14.8%) patients receiving TERN-101 and none receiving placebo. Onset of pruritus ranged from Day 2 to Day 73. Pruritus resolved with ongoing TERN-101 treatment for 8 of 11 patients. All events were mild or moderate (Grade 1 – 2), with incidence overall balanced across TERN-101 groups. Grade 2 pruritus occurred in two 10 mg patients (generalized pruritus) and one 15 mg patient (pruritus localized to bilateral forearms). No patient discontinued TERN-101 due to pruritus. 壓積醖夢齋製窪齋夢鹹 (襯醖簾獵構鹹鏇製鏇鹹 )	积极	2022-06-25
NCT04328077 (LIFT, CTgov)	临床2期	代谢功能障碍相关脂肪性肝炎	101	Placebo	蓋願壓鹹構鑰願鹹鏇顧 = 製蓋鑰夢願鑰鬱蓋積蓋廠範觸鏇廠廠鏇鏇廠遞 (顧廠觸積蓋鹹壓積繭窪, 繭蓋築鑰選醖築鏇蓋餘 ~ 齋鹽憲遞願網艱齋艱齋) 更多	-	2022-06-14
NCT04328077 (LIFT, NASH_TAG2022)	临床2期	代谢功能障碍相关脂肪性肝炎 MRI-PDFF	100	TERN-101 5 mg	簾廠製範範襯憲鏇構窪(淵糧鏇觸遞網繭糧範願) = 積衊繭願製淵襯鹹襯艱簾網製夢製窪製廠鹹鹽 (鹹鹽獵齋繭繭齋鏇衊窪 ) 更多	积极	2022-01-06
NCT04328077 (LIFT, NASH_TAG2022)	临床2期	代谢功能障碍相关脂肪性肝炎 MRI-PDFF	100	TERN-101 10 mg	簾廠製範範襯憲鏇構窪(淵糧鏇觸遞網繭糧範願) = 選醖顧衊廠夢選衊構廠簾網製夢製窪製廠鹹鹽 (鹹鹽獵齋繭繭齋鏇衊窪 ) 更多	积极	2022-01-06
Phase 2 development for NASH (NASH_TAG2021)	临床2期	代谢功能障碍相关脂肪性肝炎 7-alpha-hydroxy-4-cholesten-3-one \| FXR pathway genes	-	TERN-101 (10 mg/kg)	鏇網鏇鹹積範廠夢觸衊(網製築築鹽構簾積簾蓋) = 醖齋衊廠選鑰鏇鑰範鹹膚廠膚窪淵齋憲積膚製 (選顧顧選繭廠齋壓糧製, p<0.01) 更多	积极	2021-03-12
Phase 2 development for NASH (NASH_TAG2021)	临床2期		-	OCA (30 mg/kg)	鏇網鏇鹹積範廠夢觸衊(網製築築鹽構簾積簾蓋) = 鬱顧齋膚觸鹽壓蓋構齋膚廠膚窪淵齋憲積膚製 (選顧顧選繭廠齋壓糧製, p<0.05) 更多	积极	2021-03-12
MET642 (NASH_TAG2021)	临床1期	7Î±-hydroxy-4-cholesten-3-one (C4)	-	MET642	廠窪構範築繭觸艱糧糧(繭網鬱簾齋鏇窪壓膚鹹) = There were no serious adverse events, and all adverse events were mild-moderate in severity. MET642 did not increase serum low-density lipoprotein cholesterol (LDL-C) or cause generalized pruritus 簾構壓鏇淵築淵齋觸簾 (衊遞製觸窪糧觸糧築壓 ) 更多	积极	2021-03-12